Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Emerging Company Profile

Kymab: More mAb diversity

Wellcome backing Kymab's Kymouse to create diverse human antibodies

Stephen Hansen Senior Writer
February 27, 2012 8:00 AM UTC

Kymab Ltd. is developing its Kymouse transgenic mouse platform to generate a greater repertoire of human mAbs than it says can be done with competing technologies. With the Wellcome Trust backing the newco, management plans to build an internal therapeutic pipeline and partner the technology on a non-exclusive basis.

The diversity of mAbs generated by a transgenic mouse platform is determined by three key factors, according to Kymab Chairman and CEO Andrew Sandham...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article